Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 5230  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5062    
    Printed137    
    Emailed4    
    PDF Downloaded315    
    Comments [Add]    
    Cited by others 4    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2009  |  Volume : 57  |  Issue : 6  |  Page : 756--763

Primary central nervous system lymphoma: A profile of 26 cases from western India


1 Department of Neurology, Bombay Hospital Institute of Medical Sciences, 12, New Marine Lines, Mumbai 400 020, Maharashtra, India
2 Department of Oncology, Bombay Hospital Institute of Medical Sciences, 12, New Marine Lines, Mumbai 400 020, Maharashtra, India

Correspondence Address:
Pankaj A Agarwal
Department of Neurology, Room No. 131, 1st Floor, MRC Building, Bombay Hospital Institute of Medical Sciences, 12, New Marine Lines, Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.59472

Rights and Permissions

Background : Primary central nervous system (CNS) lymphoma (PCNSL) is a rare malignant non-Hodgkin's lymphoma and it accounts for 1% of all intracranial tumors. Only a few PCNSL studies have been reported from India, and studies on prognostic factors determining outcome, or evaluation of the response to currently accepted treatment, are lacking. Aims : This study attempts to further delineate the clinical, radiological and pathological profile of PCNSL in India, to evaluate response to treatment and to assess usefulness of the International Extranodal Lymphoma Study Group (IELSG) score. Settings and Design : All patients with pathologically proven PCNSL admitted over three years at a large tertiary care institution were studied. Materials and Methods : Clinical features, IELSG prognostic score, imaging and pathological features, and response to treatment were evaluated. Results were analyzed using χ 2 test. Results : Of 26 patients found, all except two were immunocompetent. Median age at diagnosis was 59 years. Focal deficits (76.9%) and neuropsychiatric symptoms (57.6%) were the commonest presenting complaints. Except for one case, at least some contrast enhancement was seen in brain lesions of all patients. Pathological studies showed high grade diffuse large B-cell (DLBCL) histology in 96.2% of patients. Of 22 patients who received methotrexate (MTX) based chemotherapy with/without radiotherapy; six died, with a response rate of 72.7%. Median survival was 10 months. Median follow-up duration was 14.5 months. Four patients developed treatment-related cognitive decline. All six patients with IELSG score of 4/5 died, while all 16 patients with a score of 0-3 survived. Conclusions : PCNSL presents most commonly in the sixth decade with focal neurological deficit, behavioral symptoms and cognitive decline. High grade DLBCL is the commonest histological subtype. Steroids should ideally be withheld until biopsy as they may confound the diagnosis. Most immunocompetent patients respond well to high dose MTX-based chemotherapy with/without radiation. High IELSG scores correlate with worse prognosis in patients with PCNSL






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow